VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
VENT-03
Phase 2
Small molecule
V
Ventus Therapeutics U.S., Inc.
1
Indications
1
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cutaneous Lupus Erythematosus (CLE)
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cutaneous Lupus Erythematosus (CLE)
Phase 2
Recruiting
Clinical
Trials by Indication
[1]
Cutaneous Lupus Erythematosus (CLE)
1 trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
Recruiting
·
V
Ventus Therapeutics U.S., Inc.
·
Phase 2
·
NCT07260877
·
24 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for VENT-03. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
VENT-03 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for VENT-03. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Ventus Therapeutics U.S., Inc. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 2
[1]
Company
V
Ventus Therapeutics U.S., Inc.
Related News